111 results about "Lipid blood" patented technology

The invention provides a multi-source heterogeneous data integrated coronary heart disease accurate prediction method, which comprises the following steps: acquiring various physiological signals of a patient in real time, the physiological signals comprising ST segment change characteristics and basic cycle function parameters in electrocardiosignals, and obtaining a multi-source signal data set; according to the joint data set, analyzing instantaneous fluctuation characteristics of a vascular resistance index in a postprandial hyperlipemia window period, extracting a vascular resistance fluctuation amplitude from the instantaneous fluctuation characteristics, and if it is detected that the fluctuation amplitude exceeds a preset threshold range, marking the window as a high-risk time window; if the score value exceeds a preset threshold value, triggering a coronary heart disease early warning signal according to the comprehensive risk score value in combination with a feature mode of a coronary heart disease hidden period in historical data; and storing the current high-risk time window characteristics and the blood sugar and blood fat curve change trend through a triggered coronary heart disease early warning signal to obtain structured risk archive data.

The invention provides a cardiovascular and cerebrovascular disease risk prediction method and system, and relates to the technical field of data processing.The method comprises the steps that real-time physiological parameters of a target user are obtained, and the real-time physiological parameters comprise the ambulatory blood pressure fluctuation rate, the serum lipoprotein level, the heart rate variability frequency domain index and the sleep apnea hypopnea index; the method comprises the following steps: preprocessing real-time physiological parameters, extracting instantaneous waveform features of blood pressure signals by adopting wavelet transform, and extracting features related to health conditions, including blood pressure level, blood fat level, blood sugar level, electrocardiogram abnormal indexes and cardiac ultrasound abnormal indexes, to form a feature vector set; according to the method, the real-time physiological parameters are acquired, the feature vector set is formed through preprocessing, the krill swarm algorithm is used for optimization, the three-level fusion model is constructed, finally, the cardiovascular and cerebrovascular disease risk degree of the target user is accurately evaluated, early warning information is output, and the accuracy and timeliness of cardiovascular and cerebrovascular disease risk prediction are effectively improved.

The present invention is directed to substituted 1-(1H-imidazol-1-yl)-3-methyl-2- phenylbutan-2-ol and 1-cyclopentyl-2-(1H-imidazol-1-yl)-1-phenylethan-1-ol compounds useful as agonists of 8-oxo-guanine DNA glycosylase (OGG1) in humans, as well as pharmaceutical compositions comprising them and methods of their use in treating diseases, including metabolic syndrome, obesity, fatty liver disease, dyslipidemia, insulin resistance, neurodegenerative disorders and cancers.

The present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of such fixed dose combinations, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The invention belongs to the technical field of microorganisms and biological medicines, and particularly relates to marine-source lactobacillus plantarum HYC-1 with cholesterol lowering and alpha-glucosidase inhibiting activity and application of the marine-source lactobacillus plantarum HYC-1. The novel lactobacillus plantarum HYC-1 is screened from intestinal tracts and contents of marine fishes, the strain has efficient cholesterol lowering activity and alpha-glucosidase inhibition activity at the same time, and experimental results show that the in-vitro cholesterol lowering rate of lactobacillus plantarum HYC-1 fermentation liquor can reach 89.4%, the alpha-glucosidase inhibition rate can reach 93.5%, and the lactobacillus plantarum HYC-1 fermentation liquor can be used for preparing the cholesterol lowering agent. One bacterium has double effects and unique functions; besides, the strain shows excellent tolerance and high safety, so that the strain can be widely applied to food, health care products and medicines, especially to preparation and research and development of medicines with the efficacy of regulating blood fat and blood sugar.

The invention provides a quadruple test method for inflammatory factor markers CRP, SAA, PCT and IL-6, and belongs to the technical field of biological detection. According to the present invention, the digital fluorescence immunoassay technology is adopted, the antibodies are immobilized on the detection plate, and after the antigen in the sample is combined with the immobilized antibodies, the fluorescein-labeled antibody is combined with the other antigen determinant on the antigen so as to detect the antigen in the sample; therefore, a sandwich type compound structure is constructed between the immobilized antibody and the fluorescein labeled antibody, the higher the antigen concentration is, the more the fluorescent particles are, and the content of the antigen is quantified through the number of the fluorescent particles. By means of the unique design, high-sensitivity and high-precision detection of antigens can be achieved, the content of the antigens can be accurately quantified by accurately counting the number of the fluorescent particles, the influence of lipemia / hemolysis on the detection result can be avoided, the detection range is wide, sensitivity is high, accuracy is high, and detection is automatic, convenient and rapid.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

The present application discloses a sample analysis system and a sample analysis method, an electronic device and a storage medium, wherein the sample analysis method comprises: an electronic device acquires at least two images of a sample container; the at least two images are processed to obtain a sample analysis result of the sample container; wherein the sample analysis result characterizes a sample classification corresponding to the blood sample in the sample container; the sample classification comprises a normal sample, or comprises at least one of a hemolytic sample, a icteric sample and a lipemia sample; when the sample analysis result is at least one of a hemolytic sample, a icteric sample and a lipemia sample, the sample container is dispatched to a biochemical analysis device for serum index detection and / or biochemical item detection; the detection of biochemical items is performed when the serum index of the blood sample in the sample container is normal.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention discloses a traditional Chinese medicine constitution identification method and device, a storage medium and a server. The method comprises the following steps: acquiring a human face spectrum sample and blood fat contents of a tested crowd; inputting the human face spectrum sample into a pre-constructed hyperlipidemia risk prediction model to obtain a target human face spectrum sample with hyperlipidemia in the tested crowd and a first target blood fat four-item content corresponding to the target human face spectrum sample; making corresponding labels on the basis of the target face spectrum samples, corresponding first target blood fat four-item contents and traditional Chinese medicine constitution categories, and training the model through training samples obtained by making the corresponding labels to obtain a traditional Chinese medicine constitution identification model; obtaining a to-be-detected human face spectrum sample, and inputting the sample into the traditional Chinese medicine constitution identification model to obtain the content of four second target blood lipids suffering from hyperlipidemia in the detected crowd and a traditional Chinese medicine constitution identification result corresponding to the content of the four second target blood lipids; the technical problem that enough support cannot be accurately provided for treatment and prevention of patients with the lipemia is solved.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention discloses a method for weakening the influence of lipemia on transmission-scattering fusion enhanced immunoturbidimetry detection. The method specifically comprises the following steps: S1, measuring the mean value of absorbance signal values of photometric points in a specific section after a reaction buffer solution is added into each sample; s2, measuring non-lipid turbidity values of different samples which do not cause low scattering measurement after each sample is added into the reaction buffer solution, namely, a background; s3, comparing the value measured in the step S1 with the value measured in the step S2 so as to judge whether the scattering turbidimetry measurement result needs to be revised or not; the invention relates to the technical field of transmission-scattering fusion enhanced immunoturbidimetry detection. According to the method for weakening the influence of the lipid blood on the transmission-scattering fusion enhanced immunoturbidimetric assay, when the transmission-scattering fusion enhanced immunoturbidimetric assay is carried out, the turbidity of fat particulate matters in a lipid blood sample is strongly correlated with a transmission turbidity signal value of the sample added into a reaction buffer solution, so that the influence of the lipid blood on the transmission-scattering fusion enhanced immunoturbidimetric assay is reduced; meanwhile, the relevance is specifically numeralized through the transmission light absorbance value of the sample and the R1.

The present invention provides a method of increasing glycemic control in a patient in need thereof by administering tizatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method of improving body weight management in a patient in need thereof by administering tizatide, or a pharmaceutically acceptable salt thereof. Also provided is a method of treating a condition selected from the group consisting of atherosclerosis, chronic kidney disease, NAFLD and NASH. Also provided is a method of preventing or causing alleviation of diabetes mellitus, comprising administering tizatide or a pharmaceutically acceptable salt thereof. Also provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

The invention discloses a traditional Chinese medicine composition for treating middle-jiao type diabetes as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15-30 parts of herba eupatorii, 10-20 parts of radix astragali, 8-15 parts of radix codonopsis, 1-3 parts of gypsum, 6-12 parts of radix rehmanniae preparata, 6-12 parts of radix rehmanniae recen, 9-15 parts of Chinese yam, 18-30 parts of radix trichosanthis, 12-20 parts of rhizoma anemarrhenae, 12-20 parts of radix ophiopogonis, 9-15 parts of dendrobe, 9-15 parts of radix polygonati officinalis, 3-6 parts of safflower, 3-6 parts of coptis chinensis, 9-15 parts of radix scrophulariae, 9-15 parts of dogwood, 6-10 parts of liquorice and 9-15 parts of seville orange flower. , 9-15 parts of loquat flower, 6-12 parts of penthorum chinense pursh and 6-12 parts of angelica keiskei. The traditional Chinese medicine composition is suitable for nourishing yin, moistening the lung, clearing the stomach, clearing heat, moistening dryness and promoting the secretion of saliva or body fluid, has a positive regulation effect on blood sugar and blood fat of diabetes patients, and is used for middle-digestion diabetes.

1. Name of the product in this design: Blood Lipid Detector. 2. Purpose of this design: For measuring blood lipids. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The invention belongs to the technical field of cardiovascular disease treatment medicines, and particularly relates to a traditional Chinese medicine composition for qi deficiency, blood stasis and phlegm stagnation type coronary heart disease as well as a preparation method and application thereof. The traditional Chinese medicine composition comprises codonopsis pilosula, astragalus membranaceus, dogwood, rhizoma anemarrhenae, platycodon grandiflorum, radix bupleuri, rhizoma cimicifugae, rhizoma sparganii, curcuma zedoary, cassia twig, trichosanthes kirilowii maxim, allium macrostemon, rhizoma pinelliae preparata, Chinese yam and honey-fried licorice root. The traditional Chinese medicine composition can tonify qi, activate blood, eliminate phlegm and resolve turbidity, can be used for treating qi deficiency, blood stasis and phlegm stagnation type coronary heart disease, and can treat both symptoms and root causes. Experiments prove that for a mouse with coronary heart disease, the traditional Chinese medicine composition can obviously improve the heart function of the mouse, and has the effects of inhibiting atherosclerosis and regulating lipid metabolism; for patients with qi deficiency, blood stasis and phlegm stagnation type coronary heart disease, the traditional Chinese medicine composition can improve the symptoms of chest pain and chest distress of the patients. Therefore, the traditional Chinese medicine composition can be used for preparing a medicine for treating qi deficiency, blood stasis and phlegm stagnation type coronary heart disease, and can also be used for preparing a medicine for regulating blood fat.

The invention discloses an application of N1, N10-dicaffeoyl spermidine in preparation of a medicine for preventing and treating atherosclerosis. Belongs to the technical field of biological medicine. When the N1, N10-dicaffeoyl spermidine is administered to an experimental animal within the dosage range of 10-25 mg / kg, the area of ApoE- / -mouse atherosclerotic plaque induced by high homocysteine (HCY) can be remarkably reduced, meanwhile, the HCY level, the levels of four blood lipid items (TG, TC, LDL-C and HDL-C) and the levels of inflammatory factors such as IL-6, IL-1beta, TNF-alpha, MCP-1 and CRP in serum of the atherosclerotic mouse can be remarkably callback, and the N1, N10-dicaffeoyl spermidine can be used for treating atherosclerotic mice. All the results prove that the N1, N10-dicaffeoyl spermidine has the effect of improving the atherosclerosis and can be used for preventing and treating cardiovascular system diseases such as the atherosclerosis.

Provided herein are incretin analog compounds that are GLP-1 / GIP / Gcg receptor triple agonists and their medical use in the treatment and / or prevention of a disease such as dyslipidemia, fatty liver disease, metabolic syndrome, MASH, MAFLD, obesity and T2DM.

The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and / or prevention of dyslipidemic diseases, disorders, and / or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.

Disclosed herein are compounds suitable for use in the treatment of disorders, e.g., diabetic disorder, a dyslipidemia disorder, a cardiovascular disorder, an inflammatory disorder, a hepatic disorder, cancer, or obesity or co-morbidities thereof. Also disclosed are compositions containing one or more of the compounds and uses of the compounds in the treatment of disorders in a subject.

1. Name of the design product: Tester accessory connector. 2. Use of the design product: It is used for the connection port of the test strip card of blood glucose, blood lipid, and uric acid tester devices. 3. Design key points of the design product: Lies in the shape. 4. Picture or photo that best shows the design key points: Perspective view 1.

The present disclosure relates to once-weekly dosing regimens, formulations, and methods of using dual agonists of GLP-1R and GCGR to treat cardiovascular diseases / disorders and / or reduce their risk factors by inducing a reduction in pathogenic serum lipid mediators in humans, who may or may not have other comorbidities such as obesity and / or type 2 diabetes. The dual agonist of GLP-1R and GCGR includes the peptide product of SEQ ID NO: 1 (pembidutide).

Aspects of the disclosure relate to compositions and methods for multiplexed gene silencing in a cell or subject. In some embodiments, the disclosure provides an isolated nucleic acid or an rAAV encoding a transgene comprising a RNA-guided nuclease (RGN) operably linked to a first promoter, and a second promoter operably linked to a multi guide-RNA (multi-gRNA) expression cassette encoding one or more gRNAs targeting a gene associated with hypercholesterolemia or dyslipidemia. In some embodiments, the disclosure provides methods of treating a subject having hypercholesterolemia or dyslipidemia by administering the compositions.

A polypeptide that is active against each of a GIP, a GLP-1, and a glucagon receptor is provided. The polypeptides have structural features that result in each of the receptors having activity and extended action time. Also provided are methods for treating diseases and / or conditions such as obesity, long term weight management, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, chronic kidney disease (CKD), osteoarthritis (OA), obesity-associated sleep apnea (OSA), and polycystic ovarian syndrome (PCOS).

The present invention relates to GLP-1 / GIP / GCG triple receptor agonists and their use in the treatment or prevention of type 2 diabetes (T2DM), hyperlipidemia / dyslipidemia, metabolic syndrome, metabolic dysfunction-related fatty liver disease (MASLD), metabolic dysfunction-related steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risk and / or obesity.

Prenylated tetrahydroquinolines and quinolines and pharmaceutical compositions comprising the same. Prenylated tetrahydroquinoline and quinolines and pharmaceutical compositions comprising the same, for use in the prevention and / or treatment of peroxisome proliferator-activated receptor (PPAR)-mediated diseases such as metabolic syndrome, type 2 diabetes mellitus, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, dyslipidemic atherosclerosis, metabolic dysfunction- associated fatty liver disease (MAFLD), cardiovascular disease, cardiometabolic disease, neurodegenerative disease, Friedreich's ataxia, Parkinson's disease, multiple sclerosis, Alzheimer's disease, autoimmune disease, rheumatoid arthritis, autoimmune thyroid disease, dermatological disease, and cancer.

The invention provides a lipid index quality control product as well as a preparation method and application thereof. The lipid index quality control product comprises serum, a fat emulsion injection and a preservative; the serum, the fat emulsion injection and the preservative are mixed according to different preset proportions to obtain quality control products with different lipid indexes; the preset proportion is that the volume ratio of the serum to the fat emulsion injection to the preservative is 100: (2-10): (0.05-0.1); the preservative is 0.05% of sodium azide. By applying the provided lipid index quality control product, the accuracy and stability of a detection system on a lipid blood sample can be evaluated, and the reliability of a detection result in the presence of lipid interference is ensured.

The invention discloses a long-acting GLP-1 / GIP / Y2 receptor triple agonist as well as a preparation method and application thereof, the amino acid sequence of the receptor triple agonist is as shown in the following general formula (I), and the receptor triple agonist can act on a GLP-1 receptor, a GIP receptor and a Y2 receptor at the same time and can play the activities of GLP-1, GIP and PYY at the same time. The GLP-1 / GIP / Y2 receptor triple agonist disclosed by the invention has the effects of effectively reducing blood sugar and weight and regulating lipid. The compound has greater potential when being applied to medicines for treating metabolic syndromes, such as diabetes, obesity, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis, dyslipidemia and other diseases. # imgabs0 #

Oligonucleotides and compositions including the same are disclosed that modulate (e.g., inhibit, limit or reduce) sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) activity. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders, and / or conditions associated with SCAP activity such as nonalcoholic fatty liver disease (NAFLD), (NASH), dyslipidemia, atherosclerotic cardiovascular disease (ASCVD), and / or other SCAP-associated conditions, diseases, and / or disorders.

The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin / kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.